Elcelyx Therapeutics, Inc.

Amylin Pharmaceuticals, Inc.

Anji Pharma (us) LLC

Anji Pharmaceuticals Inc.

Arena Pharmaceuticals, Inc.

Lipidio Pharmaceuticals Inc.

Anji Pharma LLC

Nigel R A Beeley

Alain D Baron

Mark S Fineman

Kathryn Susan Prickett

Andrew A Young

Will Vine

Derek T Chalmers

Dominic P Behan

Sonja Strah-Pleynet

Keith Johnson

Frédérique Menzaghi

Charles Rodney Greenaway Evans

Kevin Beaumont

Martin R Brown

Christopher R G Jones

Kieran George Mooney

J Gordon Foulkes

Howard G Welgus

Celia P Jenkinson

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

Compositions and methods for treating metabolic disorders

Pharmaceutical carriers which provide an environment of physical and chemical stability comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound of structure I, one or more antioxidants, one or more chelators and a vehicle base comprising water and one or more pharmaceutically acceptable non-aqueous solvents, one or more absorption enhancers, one or more gelling agents and one or more pH buffering agents are described.

Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Chemosensory receptor ligand-based therapies

Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.

Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Growing community of inventors

Solana Beach, CA, United States of America

Nigel R A Beeley